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A genome-wide association scan of the Genetics of Kidneys
in Diabetes (GoKinD) collections identified four novel
susceptibility loci, located on chromosomes 7p14.3, 9q21.32,
11p15.4, and 13q33.3 associated with type 1 diabetic
nephropathy. A recent evaluation of these loci in Japanese
patients with type 2 diabetes supported an association at the
13q33.3 locus. To follow up these findings, we determined
whether single-nucleotide polymorphisms (SNPs) at these
same four loci were associated with diabetic nephropathy
in the Joslin Study of Genetics of Nephropathy in Type 2
Diabetes collection. A total of 6 SNPs across these loci were
genotyped in 646 normoalbuminuric controls and in 743
nephropathy patients of European ancestry. A significant
association was identified at the 13q33.3 locus (rs9521445:
P¼ 4.4 103). At this same locus, rs1411766 was also
significantly associated with type 2 diabetic nephropathy
(P¼ 0.03). Meta-analysis of these data with those of the
Japanese and GoKinD collections significantly improved the
strength of the association (P¼ 9.7 109). In addition, there
was a significant association at the 11p15.4 locus (rs451041:
P¼ 0.02). Thus, associations identified in the GoKinD
collections on chromosomes 11p15.4 (near the CARS gene)
and 13q33.3 (within an intergenic region between MYO16
and IRS2) are susceptibility loci of kidney disease common to
both type 1 and 2 diabetes.
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Diabetic nephropathy affects approximately 30–40% of all
patients with either type 1 or type 2 diabetes and remains the
leading cause of end-stage renal disease (ESRD) in the United
States.1–3 In type 2 diabetes, in particular, the burden of this
devastating complication continues to grow worldwide. Yet,
despite evidence that suggests that heritability contributes to
its increased susceptibility, the genetic factors underlying its
susceptibility remain largely unknown.4–9
In a recent genome-wide association (GWA) scan of
participants from two independent collections of the
Genetics of Kidneys in Diabetes (GoKinD) study, we
identified four distinct chromosomal regions that were
associated with advanced nephropathy (proteinuria and
ESRD) in type 1 diabetes.10 Although none of the single-
nucleotide polymorphisms (SNPs) identified in GoKinD
achieved genome-wide significance (Po5.0 108), moder-
ate levels of significance (Po1 105) occurred on chromo-
some 9q21.32 near the FERM domain-containing 3 (FRMD3)
gene, on chromosome 7p14.3 at the b-chimerin isoform
2/serine carboxypeptidase vitellogenic-like (CHN2/CPVL)
locus, on chromosome 11p15.4 at the cysteinyl-tRNA
synthetase (CARS) gene, and on chromosome 13q33.3 at
an intergenic region telomeric to the myosin heavy-chain
Myr 8 (MYO16) gene and centromeric to the insulin receptor
substrate 2 (IRS2) gene.
Evidence of association at the 9q21.32, 11p15.4, and
13q33.3 loci with severe nephropathy was also observed
among Caucasian participants with 419,000 person-years of
follow-up from the DCCT/EDIC (Diabetes Control and
Complications Trial/Epidemiology of Diabetes Interventions
and Complications) study.10 Replication in this prospective
cohort study significantly bolsters the importance of these
findings and remains the strongest evidence to date in
support of the associations at these loci. In addition, further
evidence implicating the 13q33.3 locus at risk of nephropathy
was gained from a subsequent study that identified a
chromosomal region at the homologous region on mouse
chromosome 8, which was strongly associated with increased
albuminuria in mice.11
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More recently, examination of SNPs at the 7p14.3,
9q21.32, 11p15.4, and 13q33.3 loci in a large collection of
Japanese patients with type 2 diabetes provided additional
support of the association at chromosome 13q33.3, suggest-
ing that this region may harbor a susceptibility locus
common in both type 1 and type 2 diabetic nephropathy.12
Given the current lack of GWA data for diabetic nephropathy
in type 2 diabetes, in this study, we performed a focused
evaluation of the same four loci followed up in this type 2
cohort to investigate whether genetic variants at these loci are
associated with diabetic nephropathy in the Joslin Study of
Genetics of Nephropathy in Type 2 Diabetes collection.
RESULTS
A total of 1389 patients of European ancestry from the Joslin
Study of Genetics of Nephropathy in Type 2 Diabetes
collection, including 743 patients with diabetic nephropathy
(427 cases with microalbuminuria and 316 cases with
proteinuria, of whom 59 progressed to ESRD) and 646
controls with no clinical evidence of kidney complications
(persistent normoalbuminuria) were included in this study.
Baseline clinical characteristics for these patients are provided
in Table 1.
Six SNPs across four loci were selected for genotyping in
the Joslin Study of Genetics of Nephropathy in Type 2
Diabetes collection.10 In the GoKinD collections, strong
associations were identified at two highly correlated SNPs on
chromosome 7p14.3 (rs39059 and rs39075, r2¼ 0.96) located
within the CHN2 gene and upstream of CPVL. Similarly, on
chromosome 11p15.4, strong associations were identified at
rs739401 and rs451041 (r2¼ 0.97) within the CARS gene.
From each locus, the most strongly associated SNPs (7p14.3:
rs39075 and 11p15.4: rs451041) were selected for geno-
typing in the Joslin Study of Genetics of Nephropathy in
Type 2 Diabetes collection. In addition, two SNPs (namely
rs1888747 and rs10868025) sharing partial linkage disequili-
brium (r2¼ 0.81) on chromosome 9q21.32 (located upstream
of FRMD3) were also strongly associated with diabetic
nephropathy in the GoKinD collections and selected for
genotyping. Finally, multiple highly correlated SNPs on
chromosome 13q33.3 were also identified in the GoKinD
collections. Owing to the extent of linkage disequilibrium
shared among these variants, only two SNPs (rs1411766 and
rs9521445) with minimal linkage disequilibrium among all
other SNP pairs (r2¼ 0.30–0.65) were included in this study.
Recent studies have suggested that the development of
diabetic nephropathy and its progression may be influenced
by different genetic factors.13,14 To test this hypothesis, we
first analyzed the SNPs at chromosomes 7p14.3, 9q21.32,
11p15.4, and 13q33.3 for association with early and advanced
diabetic nephropathy by stratifying cases from the Joslin
Study of Genetics of Nephropathy in Type 2 Diabetes
collection based on their stage of disease. Separate analyses
compared the distribution of risk alleles for each SNP among
cases with either microalbuminuria or proteinuria/ESRD
versus normoalbuminuric controls, respectively (Table 2).
The effects at rs39075 (7p14.3), rs10868025 (9q21.32),
rs451041 (11p15.4), and rs9521445 (13q33.3) were of similar
magnitude among cases from this collection irrespective of
their nephropathy stage. In contrast, rs1411766 on chromo-
some 13q33.3 was exclusively associated with the risk of early
diabetic nephropathy (odds ratio (OR)¼ 1.34, 95% con-
fidence interval (95% CI)¼ 1.11–1.61, P¼ 1.9 103 for
comparison of microalbuminuric cases and OR¼ 1.01, 95%
CI¼ 0.82–1.24, P¼ 0.94 for comparison of proteinuric/ESRD
cases). No significant deviation from the Hardy–Weinberg
equilibrium was observed among the genotype distributions
for the six SNPs included in this study in either the case or
the control group (P¼ 0.09 for rs39075, P40.34 for all other
SNPs tested).
Next, we assessed associations between SNPs across these
four distinct susceptibility loci and diabetic nephropathy in
the entire Joslin Study of Genetics of Nephropathy in Type 2
Diabetes collection (646 control and 743 case subjects). After
adjustment for multiple testing, rs9521445 (OR¼ 1.25, 95%
CI¼ 1.07–1.46, P¼ 4.4 103) on chromosome 13q33.3
showed significant evidence of association among the
samples in this collection (Table 2). At this same locus,
rs1411766 was also associated with type 2 diabetic nephro-
pathy (OR¼ 1.19, 95% CI¼ 1.01–1.40, P¼ 0.03). However,
this SNP does not achieve statistical significance when a
conservative Bonferroni’s correction is applied (Bonferroni-
corrected P¼ 0.18). In addition, we also observed an
association at the 11p15.4 locus (rs451041: OR¼ 1.21, 95%
Table 1 | Baseline clinical characteristics of the Joslin Study of Genetics of Nephropathy in Type 2 Diabetes collection
Joslin Study of Genetics of Nephropathy in Type 2 Diabetes collection
Clinical characteristic Controls Microalbuminuria cases Proteinuria/ESRD cases
n 646 427 316
Men/women 320/326 302/125 228/88
Age at type 2 diabetes diagnosis (years) 44.8±8.7 44.0±8.2 42.9±8.6
Duration of type 2 diabetes (years) 14.9±7.7 16.9±8.4 18.0±8.5
Age at examination (years) 59.7±7.7 60.9±8.8 60.9±7.6
HbA1c (%) 7.8±1.2 7.9±1.4 8.2±1.7
BMI (kg/m2) 30.8±6.7 32.9±7.3 33.3±6.8
Cases with proteinuria/end-stage renal disease — — 257/59
ACR (mg/mg, median (25th and 75th percentiles)) 6.8 (4.2,11.4) 40 (31, 95) 593 (279, 1577)
Abbreviations: ACR, albumin-to-creatinine ratio; BMI, body mass index; ESRD, end-stage renal disease; HbA1c, glycosylated hemoglobin.
Clinical characteristics are presented as mean values±s.d.
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CI¼ 1.03–1.41, P¼ 0.02). Similarly, after accounting for the
number of SNPs analyzed in this study, rs451041 was not
significant (Bonferroni-corrected P¼ 0.12) in this collection.
Finally, we did not observe any support for associations at the
7p14.3 and 9q21.32 loci in the Joslin Study of Genetics of
Nephropathy in Type 2 Diabetes collection. Adjustments for
glycosylated hemoglobin, body mass index, and duration of
type 2 diabetes did not appreciably alter the evidence of these
associations (data not shown).
The proportion of males and females differed in the Joslin
Study of Genetics of Nephropathy in Type 2 Diabetes
collection between the case and control groups. Although
we adjusted for this difference in the analysis, further
investigation of these data by sex suggests that effect
modification may be present only at the 9q21.32 locus (data
not shown). As no association with diabetic nephropathy was
observed at this locus, and as no modification was observed
for other loci in either strata, no further analyses were
performed.
DISCUSSION
The recent examination of four loci from a GWA scan of
diabetic nephropathy in type 1 diabetes10 in Japanese patients
with type 2 diabetes12 suggests that associations on chromo-
some 13q33.3 confer increased susceptibility to nephropathy
in both type 1 and type 2 diabetes and across different ethnic
groups. To follow up these findings, we focused on the same
four loci investigated in this type 2 cohort and examined
whether SNPs at susceptibility loci on chromosomes 7p14.3,
9q21.32, 11p15.4, and 13q33.3 were associated with diabetic
nephropathy in the Joslin Study of Genetics of Nephropathy
in Type 2 Diabetes collection.
Our data, as well as those obtained from the study by
Maeda et al. (Supplementary Table S1 online), were unable to
support associations on chromosomes 7p14.3 and 9q21.32 in
type 2 diabetic nephropathy, suggesting that the increased
susceptibility due to these loci may be exclusive to type 1
diabetes. Although further studies are required to confirm
this hypothesis, evidence of the specificity of the 9q21.32
locus in type 1 diabetic nephropathy in the DCCT/EDIC
collection supports this notion.10
Variants on chromosomes 11p15.4 and 13q33.3 were
associated with disease in our analysis of the Joslin Study of
Genetics of Nephropathy in Type 2 Diabetes collection.
Associations with diabetic nephropathy at both of these
regions have now been identified in multiple independent
collections. The 13q33.3 locus was first reported to contribute
to increased susceptibility of nephropathy in a genome-wide
linkage scan of 296 ESRD-affected sibling pairs enriched for
non-diabetic nephropathy (logarithm of odds¼ 1.02 at
13q33.3 near D13S796).15 Stronger evidence of linkage was
subsequently found at this same location among 563 African-
American affected sibling pairs with all-cause ESRD, includ-
ing 267 sibling pairs with type 2 diabetes (logarithm of
odds¼ 1.72 near D13S796).16 We later reported evidence of
association at both the 11p15.4 and the 13q33.3 loci in ourT
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GWA scan of 885 type 1 diabetic controls with normoalbu-
minuria and 820 type 1 diabetic cases with advanced diabetic
nephropathy (284 with proteinuria and 536 with ESRD)
from the GoKinD collections and among 132 cases with
severe nephropathy (proteinuria or ESRD) from the DCCT/
EDIC study.10
More recently, in a study that included 3433 Japanese
patients with type 2 diabetes from 4 independent popula-
tions, including 1903 normoalbuminuric controls and 1530
advanced diabetic nephropathy cases, Maeda et al.12 reported
associations on chromosome 13q33.3 with the increased risk
of type 2 diabetic nephropathy. Their findings for rs1411766
are consistent with associations observed in both the GoKinD
collections and the Joslin Study of Genetics of Nephropathy
in Type 2 Diabetes collection. A meta-analysis combining
data for this variant from both type 2 collections improved
evidence of association at this locus (OR¼ 1.22, 95%
CI¼ 1.07–1.33, P¼ 3.8 104) (Table 3). Importantly, com-
bined data from all three studies reached genome-wide
significance (OR¼ 1.29, 95% CI¼ 1.16–1.38, P¼ 9.7 109)
(Table 3).
In the study by Maeda et al., rs9521445, a second variant
on 13q33.3 modestly correlated with rs1411766 (r2¼ 0.38 in
individuals of European ancestry, r2¼ 0.09 in individuals of
Japanese ancestry), was not found to be associated with
disease. However, a sub-analysis of Japanese patients receiv-
ing chronic hemodialysis revealed this SNP to be primarily
associated with ESRD in this population (OR¼ 1.45,
P¼ 0.02). In the present analysis, rs9521445 was significantly
associated with diabetic nephropathy in the Joslin Study of
Genetics of Nephropathy in Type 2 Diabetes collection. Both
the magnitude and the direction of this association are
consistent with that observed in GoKinD (Supplementary
Table S1 online). A meta-analysis combining our type 2 data
with those obtained from GoKinD further strengthens
evidence of this association (OR¼ 1.32, 95% CI¼ 1.19–
1.45, P¼ 7.2 108) (Supplementary Table S2 online).
To explore the possibility that two potentially independent
variants underlie the association signal at the 13q33.3
locus, we performed conditional analyses of rs1411766 and
rs9521445 in the Joslin Study of Genetics of Nephropathy in
Type 2 Diabetes and GoKinD collections. In both collections,
the association signals observed for rs1411766 were attenu-
ated after conditioning on rs9521445. Similarly, conditional
analysis revealed that rs1411766 could account for most of
the association of rs9521445, suggesting that these two signals
are not independent.
Although both 13q33.3 SNPs were of similar strength in
the GoKinD collections, rs9521445 was more strongly
associated with diabetic nephropathy in the Joslin Study of
Genetics of Nephropathy in Type 2 Diabetes collection than
rs1411766, suggesting that allelic heterogeneity at this locus
may contribute differently to the risk of disease among
patients with type 1 or type 2 diabetes and, based on
data presented by Maeda et al., these variants may also
differentially affect disease susceptibility among individuals T
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with diverse ancestral/ethnic backgrounds. Taken together,
these results further implicate this locus in the genetic
susceptibility of diabetic nephropathy. However, it remains
difficult to speculate whether variants at 13q33.3 differen-
tially affect initiation of diabetic nephropathy and/or its
progression to the advanced stages of disease and whether the
contribution of 13q33.3 to the risk of diabetic nephropathy
differs in type 1 and type 2 diabetes.
Variants at the 13q33.3 locus localize to an intergenic
regionB384 kb telomeric to MYO16 and 120 kb centromeric
to IRS2, and therefore, identifying the disease genes that
underlie these associations is likely to be particularly
challenging. However, recent studies by Pomerantz et al.17
(using chromosome confirmation capture, or 3C, at a highly
replicated colorectal cancer locus on chromosome 8q24) and
Visel et al.18 (through the targeted deletion of a coronary
artery disease-risk interval in mice) highlight successful
approaches in mapping genes located in genomic regions
devoid of protein coding genes. Similar studies will likely
be necessary to disentangle the relationship between vari-
ants at this locus and increased susceptibility to diabetic
nephropathy.
In addition, support at this locus from two SNPs in loose
linkage disequilibrium is consistent with the presence of
multiple signals in this region. As recently described by
Dickson et al.,19 multiple significant, independent associa-
tions at a single locus can be due to ‘synthetic association’
caused by rare genetic variants. Further study is required
to resolve this question and to determine whether multiple
low-frequency variants, perhaps in MYO16 or IRS2, underlie
the observed associations with diabetic nephropathy.
Similar to rs9521445 on chromosome 13q33.3, rs451041 on
chromosome 11p15.4 was not associated with type 2 diabetic
nephropathy in Japanese patients (Supplementary Table S1
online). Associations at this variant were consistent in both the
GoKinD and the Joslin Study of Genetics of Nephropathy
in Type 2 Diabetes collections. A meta-analysis of these
data improved evidence of this association with diabetic
nephropathy (OR¼ 1.31, 95% CI¼ 1.16–1.43, P¼ 6.7 107)
(Supplementary Table S2 online). Although our study provides
further evidence that the 13q33.3 region is a common
susceptibility locus for diabetic nephropathy in both type 1
and type 2 diabetes, it also suggests a similar role for variants
at the chromosome 11p15.4 locus. Associations at this region
map to intron 4 of the CARS gene, a regulator of intracellular
cysteine concentrations and protein biosynthesis.20
Although associations on chromosome 11p15.4 and
13q33.3 in the Joslin Study of Genetics of Nephropathy in
Type 2 Diabetes collection further implicate these regions in
the pathogenesis of diabetic nephropathy, we acknowledge
some limitations of the our study. First, although none of the
SNPs selected for examination in this collection achieved
genome-wide significance in GoKinD, they represent the
leading loci identified in the only GWA study of diabetic
nephropathy published to date. Their examination by both
Maeda et al. and in the current study constitutes a pragmatic
strategy to investigate whether the top findings from this
GWA scan are common susceptibility loci in both type 1
and type 2 diabetic nephropathy. It does not exclude the
possibility that SNPs at other loci beyond those investigated
in these studies harbor true disease-susceptibility variants.
Second, all patients from the Joslin Study of Genetics of
Nephropathy in Type 2 Diabetes collection included in this
study were self-identified as being of Caucasian heritage.
Owing to the paucity of SNP data available in this collection,
the substructure of these samples has not been assessed.
Residual confounding as a result of undetected population
stratification could potentially lead to biases affecting the
magnitude and significance of the observed associations.
Third, this study is a focused evaluation of four loci
identified in a GWA scan of the GoKinD type 1 diabetic
nephropathy collection and recently examined in a large
cohort of Japanese patients with type 2 diabetic nephropathy.
In our study, there is 490% power to detect similar effects
as those observed in GoKinD (OR X1.30) based on a
Po0.05/6¼ 8.3 103 threshold. It should be noted that
the clinical subphenotypes of our collection produce
some uncertainty in the estimation of this effect and its
interpretation. Moreover, we note that applying the ‘Winners
Curse’ correction to the effect sizes at each of the four loci
would result in an overestimation of the power of this study
for a fixed sample size.
Despite these limitations, our analysis increases support
that associations identified in the GoKinD collections on
chromosomes 11p15.4 (near the CARS gene) and 13q33.3
(within an intergenic region between MYO16 and IRS2) are
true diabetic nephropathy susceptibility loci common to both
type 1 and type 2 diabetes. Further characterization of these
regions is necessary to define both the predisposing variants
and the disease genes underlying these associations.
PATIENTS AND METHODS
Study patients
The Joslin Clinic is a large center for treatment of patients of all ages
with diabetes, as well as for treatment of late diabetic complications.
Approximately three-fourths of theB16,000 patients under the care
of the Joslin Clinic have type 2 diabetes. The clinic population is
B90% Caucasian and includes patients from all social strata. The
majority of patients reside in eastern Massachusetts and generally
come to the clinic within a few years of their diagnosis. Many
remain with the clinic for decades, receiving integrated care from
endocrinologists, nephrologists, and ophthalmologists. Computer-
ized medical records, together with laboratory measurements,
including routine determinations of urinary albumin-to-creatinine
ratio (ACR) measurements, are available for all Joslin Clinic
patients.
In the 1990s and 2000s, we recruited 2571 patients for the Joslin
Study of Genetics of Nephropathy in Type 2 Diabetes collection.
Patients were recruited in two intervals between 1991 and 1996
(n¼ 571) and between 2002 and 2008 (n¼ 2000). Patients with
microalbuminuria and proteinuria were identified in the Joslin
Clinic laboratory database and invited to participate in this study
through a special examination. In parallel to the selection and
examination of cases with diabetic nephropathy, a similar number of
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controls with normoalbuminuria was selected and invited for
examination.
The study protocol and informed consent procedures were
approved by the Committee on Human Subjects of the Joslin
Diabetes Center.
Diagnosis of type 2 diabetes, definition of nephropathy, and
patient examinations
Type 2 diabetes was considered if medical record reviews indicated
that hyperglycemia was diagnosed after 35 years of age and patients
did not require insulin therapy for at least for 2 years after their
diagnosis. The computer databases of the Joslin Clinic retain all
measurements of urinary albumin, urinary creatinine, and their
ratio (ACR) obtained for clinical and research use since 1990 and
provided the basis for diagnosing normoalbuminuria, microalbu-
minuria, or proteinuria in all clinic patients. Methods for measuring
ACR and defining normoalbuminuria, microalbuminuria, or
proteinuria were described previously.21
Study recruiters examined eligible patients during their clinic
visits. After informing patients about the study and obtaining their
written consent to participate, the recruiters administered a
structured interview that solicited the history of diabetes and its
treatment, other health problems and medications, measured seated
blood pressure (two measurements, taken 5 min apart), and
obtained blood samples for DNA and biochemical determinations
(stored at 85 1C). The questionnaire data were supplemented with
information retrieved from the Joslin Clinic medical records and
laboratory database to exclude patients with non-diabetic renal
disease.
In addition to using historical ACR measurements to identify
cases and controls for enrollment into the study, ACR measurements
obtained at least 2 years after their enrollment were used for the final
classification of patients as either cases with microalbuminuria or
proteinuria or controls with normoalbuminuria. Cases with
microalbuminuria were defined by median ACR values between 20
and 300 mg/mg in multiple follow-up measurements. Cases with
proteinuria or ESRD were defined by median ACR values 4300mg/mg
in multiple follow-up measurements or the development of ESRD
(requiring dialysis or renal transplant therapy), respectively.
Minimally, cases with microalbuminuria or proteinuria were defined
based on ACR measurements meeting these criteria in two of the
last three measurements taken at least 1 month apart. Controls
with normoalbuminuria were defined by a median value of ACR
o20 mg/mg in multiple follow-up measurements. A minimum of
two of the last three measurements taken at least 1 month apart were
required to be o20mg/mg. If a third measurement was required, a
value o40 mg/mg was necessary for inclusion.
Of the 2571 patients recruited into the Joslin Study of Genetics of
Nephropathy in Type 2 Diabetes collection as of 2008, 1400 patients
(751 with diabetic nephropathy, including 431 with microalbumi-
nuria and 320 with proteinuria, and 649 with no clinical evidence of
kidney complications and persistent normoalbuminuria despite 45
years duration of type 2 diabetes) who identified themselves as
Caucasian, had DNA extracted, had type 2 diabetes diagnosed
between 35 and 64 years of age, and were between 40 and 69 years of
age at the time of examination, were included in the current study.
The remaining 1171 patients were not included because they either
identified themselves as non-Caucasians or did not provide ethnic
information (n¼ 623), were Caucasians and normoalbuminuric but
had o5 years duration of type 2 diabetes (n¼ 43), or were
Caucasians but did not have DNA extracted at the time of initiation of
this study (n¼ 505). A total of 61 of the 320 patients with proteinuria
have progressed to ESRD since their enrollment in the Joslin Study of
Genetics of Nephropathy in Type 2 Diabetes collection.
DNA obtained from all 1400 subjects was isolated from buffy-
coat specimens (leukocytes) using a standard phenol–chloroform
extraction procedure.
Genotyping
Six SNPs across the four loci identified in the GoKinD collections
were selected for inclusion in this study, including rs39075 on
chromosome 7p14.3, rs1888747 and rs10868025 on chromosome
9q21.32, rs451041 on chromosome 11p15.4, and rs1411766 and
rs9521445 on chromosome 13q33.3. All six SNPs were genotyped
using Taqman (Applied Biosystems, Foster City, CA) technology by
the Genetics Core of the Diabetes and Endocrinology Research
Center at the Joslin Diabetes Center in accordance with the
manufacturer’s protocols.
A total of 11 samples had missing data for X3 SNPs and were
not included in our analysis. Among the remaining 1389 samples
(743 with diabetic nephropathy, including 427 with microalbumi-
nuria and 316 with proteinuria, and 646 with persistent normoal-
buminuria), the overall genotype success rate was 498% for all
SNPs, with the exception of rs10868025, which had a success rate of
92%. The concordance rate among duplicate samples was 100% for
all six genotyped SNPs.
Statistical analysis
Deviation from the Hardy–Weinberg equilibrium was assessed for
using a genotypic w2 test. All SNPs were analyzed using stratified
additive tests of association, adjusting for gender, using the
Cochran–Mantel–Haenszel test procedure as implemented in
PLINK.22 The effects of gender, glycosylated hemoglobin, body
mass index, and duration of type 2 diabetes on these associations
were assessed using logistic models. Combined meta-analyses of the
Joslin Study of Genetics of Nephropathy in Type 2 Diabetes
collection, Japanese Type 2 Diabetes Diabetic Nephropathy collec-
tion,12 and GoKinD10 collections were performed using the
Cochran–Mantel–Haenszel method with fixed-effects models. Het-
erogeneity across these collections was evaluated using a Q-statistic
P-value. The I2 statistic was calculated to quantify the proportion of
the total variation due to heterogeneity.
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